CanBas Co Ltd 4575
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 456.00
- Day Range
- JPY 448.00–482.00
- 52-Week Range
- JPY 411.00–1,698.00
- Bid/Ask
- JPY 460.00 / JPY 462.00
- Market Cap
- JPY 8.33 Bil
- Volume/Avg
- 300,200 / 615,456
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 12
- Website
- http://www.canbas.co.jp
Comparables
Valuation
|
Metric
|
4575
|
4893
|
4563
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.61 | 1.24 | 0.38 |
Price/Sales | — | 21.34 | 61.87 |
Price/Cash Flow | — | — | — |
Price/Earnings
4575
4893
4563
Financial Strength
|
Metric
|
4575
|
4893
|
4563
|
|---|---|---|---|
Quick Ratio | 22.95 | 65.18 | 1.68 |
Current Ratio | 26.55 | 66.28 | 2.38 |
Interest Coverage | — | — | — |
Quick Ratio
4575
4893
4563
Profitability
|
Metric
|
4575
|
4893
|
4563
|
|---|---|---|---|
Return on Assets (Normalized) | −45.10% | −19.85% | −16.00% |
Return on Equity (Normalized) | −47.76% | −20.61% | −19.90% |
Return on Invested Capital (Normalized) | −47.76% | −20.61% | −19.26% |
Return on Assets
4575
4893
4563
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bnccpdhkm | Xjpkl | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ckhwfcvm | Ylklyg | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Llvmfwq | Tlngls | $99.5 Bil | |
MRNA
| Moderna Inc | Mrlmhqmfr | Xxdb | $38.8 Bil | |
ARGX
| argenx SE ADR | Bqmyrbnr | Gnfm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qjwzxfd | Vjrg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wbggkgnp | Gccggbj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vtdntppp | Bkwfvk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gfmvpfrcf | Qjylwt | $12.5 Bil | |
INCY
| Incyte Corp | Fpfqdkkg | Yffwrwn | $11.6 Bil |